Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/PBD antibody-drug conjugate ABBV-321

An antibody drug conjugate (ADC) consisting of ABT-806 AM1, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR), and conjugated to the cytotoxic, DNA minor groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of anti-EGFR/PBD ADC ABBV-321, the monoclonal antibody moiety of ABBV-321 targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.
Synonym:ADC ABBV-321
anti-EGFR/PBD ADC ABBV-321
Code name:ABBV 321
ABBV-321
ABBV321
Search NCI's Drug Dictionary